Apolinário A C, Figueiredo P T, Guimarães A T, Acevedo A C, Castro L C, Paula A P, Paula L M, Melo N S, Leite A F
Campus Universitário Darcy Ribeiro, University of Brasília, Brasília, Brazil.
Oral Radiology, Department of Dentistry, Faculty of Health Science, Campus Universitário Darcy Ribeiro, University of Brasília, Brasília, Brazil.
J Dent Res. 2015 Mar;94(3 Suppl):95S-102S. doi: 10.1177/0022034514567334. Epub 2015 Jan 21.
We hypothesized that mandibular cortical width (MCW) is smaller in children with osteogenesis imperfecta (OI) than in healthy children and that pamidronate can improve the cortical mandibular thickness. The aim of this study was to assess changes in the MCW on dental panoramic radiographs (DPRs) of children with normal bone mineral density (BMD) and with OI. We also compared the MCW of children with different types of OI regarding the number of pamidronate cycles and age at the beginning of treatment. MCW measurements were retrospectively obtained from 197 DPRs of 66 children with OI types I, III, and IV who were in treatment with a comparable dosage of cyclical intravenous pamidronate between 2007 and 2013. The control group had 92 DPRs from normal BMD children. Factorial analysis of variance was used to compare MCW measurements among different age groups and between sexes and also to compare MCW measurements of children with different types of OI among different pamidronate cycles and age at the beginning of treatment. No significant differences in results were found between male and female subjects in both OI and healthy children, so they were evaluated altogether (P > 0.05). There was an increase of MCW values related to aging in all normal BMD and OI children but on a smaller scale in children with OI types I and III. Children with OI presented lower mean MCW values than did children with normal BMD at the beginning of treatment (P < 0.05). A linear model estimated the number of pamidronate cycles necessary to achieve mean MCW values equivalent to those of healthy children. The thinning of the mandibular cortex depended on the number of pamidronate cycles, the type of OI, and the age at the beginning of treatment. DPRs could thus provide a way to identify cyclic pamidronate treatment outcomes in patients with OI.
我们假设,与健康儿童相比,成骨不全症(OI)患儿的下颌骨皮质宽度(MCW)更小,且帕米膦酸盐可改善下颌骨皮质厚度。本研究的目的是评估骨密度(BMD)正常和患有OI的儿童在牙科全景X线片(DPR)上MCW的变化。我们还比较了不同类型OI患儿在帕米膦酸盐治疗周期数和治疗开始时年龄方面的MCW。回顾性获取了2007年至2013年间接受类似剂量周期性静脉注射帕米膦酸盐治疗的66例I型、III型和IV型OI患儿的197张DPR上的MCW测量值。对照组有92张来自BMD正常儿童的DPR。采用析因方差分析比较不同年龄组之间以及不同性别之间的MCW测量值,并比较不同类型OI患儿在不同帕米膦酸盐治疗周期和治疗开始时年龄方面的MCW测量值。在OI患儿和健康儿童中,男性和女性受试者的结果均未发现显著差异,因此将他们一起评估(P>0.05)。在所有BMD正常和OI患儿中,MCW值均随年龄增长而增加,但I型和III型OI患儿的增幅较小。在治疗开始时,OI患儿的平均MCW值低于BMD正常的患儿(P<0.05)。线性模型估计了达到与健康儿童相当的平均MCW值所需的帕米膦酸盐治疗周期数。下颌骨皮质变薄取决于帕米膦酸盐治疗周期数以及OI类型和治疗开始时的年龄。因此,DPR可为识别OI患者的周期性帕米膦酸盐治疗效果提供一种方法。